TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was filed in Japan as a companion diagnostic for RetevmoTM (selpercatinib).
Read the full press release below:
JointRelease_RET_Selpercatinib_Apr20.2022
.pdf
Download PDF • 434KB